Delphi advisor to SpectraCure AB
Delphi has been legal advisor in connection with the listing of SpectraCure AB. First trading day was 1 July 2015.
Delphi has been legal advisor in connection with the listing of SpectraCure AB. First trading day was 1 July 2015.
SpectraCure was formed in 2003 as a spin-off company from Lund University departments for medical laser applications and physics. The company is focused on cancer treatments with medical systems using laser light source and a photosensitizing drug, which are referred to as “Interstitial Photodynamic Therapy”, PDT.
Delphi has assisted G&W Fondkommission that acted as financial advisor in the connection with the listing.
Delphi’s team consisted of Mats Dahlberg, responsible partner, assisted by Frida Lager.
Your consent means that we collect information about your device and how you use the website which is linked to what Google knows. You can withdraw your consent by, for example, clicking on “Manage cookies” in the footer at the bottom of the page or contacting us at privacy@delphi.se.
We also use necessary cookies that enable core functionality. We do not require your consent to use these cookies. You can read a detailed description on how we use cookies, how you can avoid our cookies and also how to withdraw your consent here. Our use of cookies also entails processing of your personal data. Advokatfirman Delphi Stockholm AB is the data controller and responsible for the processing, which you can read more about here. You will also find information about your rights in relation to our processing of your personal data, namely the right to withdraw your consent, the right to object to our processing, the right of access, the right to rectification, the right to erasure and restriction, the right to data portability and the right to lodge a complaint.